<DOC>
	<DOCNO>NCT01516203</DOCNO>
	<brief_summary>The purpose study assess early bacterial activity ( EBA ) day 0 day 14 Astra Zeneca Drug ( AZD5847 ) four different dos schedule ( 500 mg daily , 500 mg twice daily , 1200 mg daily , 800 mg twice daily ) subject newly-diagnosed sputum smear positive pulmonary TB . A total 75 subject enrol , 15 randomize AZD5847 study arm standard treatment Rifafour . Duration drug treatment 14 day .</brief_summary>
	<brief_title>Phase 2a EBA Trial AZD5847</brief_title>
	<detailed_description>This study early bactericidal activity ( EBA ) treatment-naïve patient active pulmonary tuberculosis . This prospective , randomize , open-label study compare effect monotherapy four dose level AZD5847 active control ( Rifafour administer orally daily ) concentration Mycobacterium tuberculosis ( M. tb ) expectorate sputum ( colony-forming unit per mL sputum ) . Daily quantitative sputum culture perform treatment analyzed investigator blind assigned treatment . The duration therapy 14 day order support assessment early bactericidal activity ( day 0-2 ) sterilize activity ( day 3-14 ) . Because risk emergence drug resistance TB patient treat single active drug , regulatory ethical requirement restrict monotherapy maximum duration 14 day ( EMEA Draft TB Guidance 2008 ) . The study utilize standard design thus support comparison market investigational antimycobacterial agent ( Donald Diacon 2008 ) . The primary aim study assess EBA 0-14 AZD5847 four different dos schedule ( 500 mg daily , 500 mg twice daily , 1200 mg daily , 800 mg twice daily ) subject newly-diagnosed sputum smear positive pulmonary TB . The secondary aim ass EBA 0-2 EBA 2-14 AZD5847 dos .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Oxazolidinones</mesh_term>
	<criteria>Adults , male female , age 18 65 year Postmenopausal woman age 65 year include study . Women childbearing potential must use agree use adequate method birth control end study follow . These method include : total sexual abstinence ; single male partner vasectomize combined use condom ; combination two effective birth control method follow list : a. intrauterine device plus condom ; b. tubal ligation ( tubes tie ) plus condom ; c. Depoprovera injection plus condom ; d. Intravaginal ring plus condom Newly diagnose sputum smearpositive pulmonary tuberculosis confirm least one sputum AFB + smear ( least grade 1+ use WHO/IUATLD grade scale ) Willing able provide inform consent Hemoglobin &gt; /= 8 gm/dL Serum creatinine &lt; 2 mg/dL ( &lt; 176.8 umol/L ) Serum AST &lt; 3.0 time upper limit normal test laboratory total bilirubin &lt; 1.3 mg/dL Random blood glucose &lt; 150 mg/dL ( &lt; 8.32 mmol/L ) If HIVpositive , currently ART , CD4 count &gt; 350 muL^1 and/or need start ART opinion local investigator Cough productive least 10 ml ( two teaspoon ) sputum daily per patient report week prior enrollment . Chest radiograph compatible pulmonary TB . Negative sputum Xpert™ MTB/RIF test rifampin resistance . Negative urine pregnancy test HIV infection CD4 count &lt; /=350muL^1 and/or need start ART opinion local investigator . Weight le 40 kg great 90 kg Presence hemoptysis . Subjects cough frank blood ( blood streak sputum ) eligible enrollment . Subjects rifampin resistance determine Xpert test screening . Pregnant breastfeed woman Presence pneumothorax pretreatment chest radiograph Clinical suspicion disseminate tuberculosis tuberculous meningitis pulmonary TB require immediate start standard chemotherapy opinion local investigator Presence serious underlie medical illness , liver failure , renal failure , diabetes mellitus , chronic alcoholism ( &gt; 3 alcoholic drink per day ) , decompensated heart failure , cardiac arrhythmia , hematologic malignancy subject receive myelosuppressive chemotherapy . Allergy contraindication study drug Prior treatment TB antituberculous medication ( isoniazid , rifampin , pyrazinamide , ethambutol streptomycin treat antibiotic know activity MTB precede 6 month ( example aminoglycosides , fluoroquinolones , carbapenems linezolid ) Subjects take monoamine oxidase ( MAO ) inhibitor selective serotonin release inhibitor ( SSRI ) medication Total white blood cell count le 3000/mm^3 Platelet count le 150,000/mm^3 Subjects QTcF &gt; 450 msec , QTcF &lt; 340 msec , and/or family history long QT syndrome Subjects unlikely opinion local investigator able comply requirement study protocol Subjects whose urine test positive INH metabolite , indicate already receive antiTB treatment . History tuberculosis le 5 year ago , history one episode tuberculosis , history drug resistant tuberculosis , household contact individual confirm drugresistant tuberculosis . Known arrhythmias cardiac condition Active severe dermatologic disease ( Grade 3 Grade 4 per DMID Adult Toxicity Table ) Immunosuppressive condition receive immunosuppressive medication A history optic neuritis . Subjects antiretroviral therapy HIV ( include AZT , 3TC , FTC , D4T , ddI , ddC , tenofovir , abacavir , nevirapine , efavirenz , ritonavir , lopinavir , atazanavir , saquinavir , darunavir , indinavir , raltegravir ) Subjects take drug capable prolong QTc interval , type Ia III antiarrhythmic Random urine toxicology screen positive cocaine methamphetamine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>AZD5847 , dose-ranging , Mycobacterium tuberculosis , Rifafour , tuberculosis</keyword>
</DOC>